Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib
Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase 2 clinical trial for Crohn's disease called FITZROY. The trial is assessing the safety and efficacy of filgotinib,Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *